Press Releases

AVROBIO Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass --(BUSINESS WIRE)--Jul. 16, 2019-- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100.0 million of its common stock in an underwritten public

Read More »
Displaying 1 - 10 of 21